Cancer Research UK (CRUK) shared a post on LinkedIn:
“Big news!
People at high risk of lung cancer will soon be able to receive the first ever experimental vaccine designed to prevent the disease, in a world-first clinical trial.
A research team from the University of Oxford and UCL have developed a vaccine called ‘LungVax’ for people at high risk of lung cancer. The scientists believe it could work by priming the immune system to recognise and kill abnormal lung cells before they become cancerous.
Lung cancer remains the leading cause of cancer death in the UK, accounting for 20% of cancer deaths each year. Because the disease can be difficult to diagnose and treat, only around 1 in 10 people diagnosed with lung cancer survive it for 10 years or more.
This new funding, from us and the CRIS Cancer Foundation, will support a clinical trial for LungVax which could begin as early as next year.
Read more in our article.”
More posts featuring Cancer Research UK.